Acquisition (Details) - Equity Component [Domain] - Business Acquisition, Acquiree [Domain] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	May. 08, 2014
Business Acquisition [Line Items]
Change in acquisition-related contingent consideration			$ (4,800,000)	$ 400,000
Revenues	$ 5,866,963	$ 4,488,932	9,039,242	8,544,507
Net loss	$ (17,158,017)	$ (12,769,492)	$ (36,389,505)	(26,599,576)
Common Stock, Shares, Issued	55,453,014		55,453,014		36,783,857	5,329,593
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High						$ 90,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net						19,400,000
Acquisition-related contingent consideration	$ 13,460,000		$ 13,460,000		$ 18,260,000	11,900,000
Business Acquisition, Transaction Costs						33,500,000
Cash and cash equivalents						51,000
Accounts receivable, net of allowance for doubtful accounts of $390,118 and $391,829 at March 31, 2014 and December 31, 2013, respectively						45,000
Prepaid expenses and other current assets						19,000
Property, plant and equipment, net						1,041,000
Other assets						201,000
Goodwill	$ 25,209,336		25,209,336		$ 25,209,336	14,092,000
Equity Issued in Business Combination, Fair Value Disclosure						21,600,000
Intangible assets, net						34,290,000
Accounts Payable, Current						(333,000)
Accrued Liabilities, Current						(2,014,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent						(13,901,000)
Deferred Tax Liabilities, Net, Noncurrent			$ 3,656,730	$ (94,796)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (0.38)	$ (0.40)	$ (0.88)	$ (0.88)
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net						$ 33,491,000
NeoStem Oncology [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue		$ 4,982,000		$ 9,255,000
Business Acquisition, Pro Forma Net Income (Loss)		(13,574,000)		(29,097,000)
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual		$ (13,409,000)		$ (28,784,000)
Business Acquisition, Pro Forma Earnings Per Share, Diluted		$ (0.36)		$ (0.82)
NeoStem, Inc. [Member]
Business Acquisition [Line Items]
Revenues		$ 4,489,000		$ 8,545,000
Net loss		(12,770,000)		(26,600,000)
Net Income (Loss) Attributable to Parent		$ (12,605,000)		$ (26,287,000)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders		$ (0.40)		$ (0.88)